ALK-Abello AS

Published Date: 22/12/2011
Category: Therapies & Markets

Research Report Decription

ALK-Abello AS - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Features:

• Detailed information on ALK-Abello AS required for business and competitor intelligence needs
• A study of the major internal and external factors affecting ALKAbello AS in the form of a SWOT analysis
• An in-depth view of the business model of ALK-Abello AS including a breakdown and examination of key business segments
• Intelligence on ALK-Abello AS’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
• News about ALK-Abello AS, such as business expansion, restructuring, and contract wins
• Large number of easy-to-grasp charts and graphs that present important data and key trends

Key Questions Answered:

• Gain understanding of the ALK-Abello AS and the factors that influence its strategies
• Track strategic initiatives of the company and latest corporate news and actions
• Assess ALK-Abello AS as a prospective partners, vendor or supplier
• Support sales activities by understanding your customers' businesses better
• Stay up to date on ALK-Abello AS’s business structure, strategy and prospects

Companies Mentioned:

ALK-Abello AS

Paper Highlights:

ALK-Abello is a pharmaceutical company engaged in the development and marketing of allergy treatment. The company is focused on allergy vaccination. Its product portfolio includes allergy diagnosis products, such as skin prick tests, immunotherapy tablets and subcutaneous immunotherapy vaccination as well as products for allergy emergency treatment, such as auto-injectors containing adrenalin. The company primarily operates in Europe. It is headquartered in Horsholm, Denmark, and employed 1,513 people as of December 31, 2009. The company recorded revenues of DKK1,935 million ($362.4 million*) during the financial year (FY) ended December 2009, an increase of 8.5% over FY2008. The operating profit of the company was DKK175 million ($32.8 million*) during FY2009, an increase of 47.1% over FY2008. The net profit was DKK118 million ($22.1 million*) in FY2009, an increase of 24.2% over FY2008. Calculated using the constant conversion rate of DKK1 = $0.18729 for the financial year ended December 31, 2009.